Vanderbilt-Ingram Cancer Center

Therapies targeted to a specific mutation in the BRAF gene can significantly reduce tumor burden in metastatic melanoma. But these therapies are not suitable for melanomas lacking the mutation, and even tumors carrying the BRAF mutation eventually become resistant to those therapies. Using human melanoma tumors implanted into mice, Ann Richmond, Ph.D., and colleagues assessed [...]